How to measure the net benefit of treatment?
Estimating net benefit makes possible to clarify the basis for therapeutic decisions on an individual and collective level. This clarification is a must in shared medical decision-making and evidence-based medicine. Numerous methods are available, although none outweigh the others. The complex specifications of net benefit estimation should be tailored to the expectations of the central stakeholder, patient or society, and the unlimited range of potential contexts. The challenges, limitations, constraints and skills to be acquired by all stakeholders were discussed by the participants of the round table. They are described in this article, enabling key messages and guidelines to be presented. The essential priority is to ensure that all stakeholders receive the required training.
UMR5558, service de pharmacologie et toxicologie, faculté Laennec, 7, rue Guillaume-Paradin, 69008 Lyon, France. Electronic address: francois.gueyffier@univ-lyon1.fr.
François
F
Gueyffier
Laboratoire Boehringer-Ingelheim, 75013 Paris, France.
Pascal
P
Piedbois
Hôpital Lariboisière, AP-HP, 75010 Paris, France.
Jean-François
JF
Bergmann
D003657:Decision Making; D019317:Evidence-Based Medicine; D006801:Humans; D017063:Outcome Assessment, Health Care; D018570:Risk Assessment
Decision analysis; Net clinical benefit; Personnalised medicine; Risk-to-benefit ratio; Shared medical decision-making